Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial

Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial

Aims Aspirin is widely used in cardiovascular disease prevention but is also associated with an increased risk of bleeding. The net effect of aspirin on dementia and cognitive impairment is uncertain. Methods and results In the ASCEND trial, 15 480 people from the UK with diabetes and no history of...

Full description

Bibliographic Details
Main Authors:	Parish, S, Mafham, M, Offer, A, Barton, J, Wallendszus, K, Stevens, W, Buck, G, Haynes, R, Collins, R, Bowman, L, Armitage, J
Other Authors:	ASCEND Study Collaborative Group
Format:	Journal article
Language:	English
Published:	Oxford University Press 2022

Similar Items

ASCEND-Eye: effects of aspirin on diabetic retinopathy
by: Sammons, E, et al.
Published: (2024)

ASCEND-eye: rationale, design and baseline characteristics for a sub-study of the ASCEND randomized trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
by: Sammons, E, et al.
Published: (2023)

ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration
by: Emily Sammons, et al.
Published: (2023-10-01)

Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
by: Parish, S, et al.
Published: (2023)

ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes
by: Bowman, L, et al.
Published: (2017)

Effects of omega−3 fatty acid supplements on arrhythmias
by: Parish, S, et al.
Published: (2020)

Comparison of routinely collected data with clinical trial adjudicated direct follow-up: post-hoc analyses of serious cardiovascular events from the United Kingdom-based ASCEND randomized trial
by: Harper, C, et al.
Published: (2021)

Comparison of the accuracy and completeness of records of serious vascular events in routinely collected data vs clinical trial–adjudicated direct follow-up data in the UK: secondary analysis of the ascend randomized clinical trial
by: Harper, C, et al.
Published: (2021)

Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial
by: Sammons, EL, et al.
Published: (2024)

Effects of aspirin and omega-3 fatty acids on composite and subdomain scores from the NEI-VFQ-25 questionnaire: the ASCEND-Eye randomized controlled trial
by: Sammons, EL, et al.
Published: (2024)

Effect of low-dose aspirin on urinary 11-dehydro-thromboxane B2 in the ASCEND (A Study of Cardiovascular Events iN Diabetes) randomized controlled trial
by: Sarah Parish, et al.
Published: (2023-03-01)

Once daily low-dose aspirin reduces urinary thromboxane B2 effectively even at 12-24 hours from dosing in the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial
by: Aung, T, et al.
Published: (2017)

Thromboxane biosynthesis and future events in diabetes: the ASCEND trial
by: Petrucci, G, et al.
Published: (2024)

Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study
by: Mafham, MM, et al.
Published: (2019)

Effects of aspirin for primary prevention in persons with diabetes mellitus
by: Bowman, L, et al.
Published: (2018)

Thromboxane metabolite excretion is associated with serious vascular events in diabetes mellitus: a sub-study of the ASCEND trial
by: Rocca, B, et al.
Published: (2020)

ASCEND-Eye: effects of omega-3 fatty acids on diabetic retinopathy
by: Sammons, E, et al.
Published: (2023)

Reliability of major bleeding events in UK routine data vs clinical trial adjudicated follow-up data
by: Harper, C, et al.
Published: (2023)

Weight loss in a cardiovascular trial population identifies people at future risk of dementia
by: van der Veere, P, et al.
Published: (2022)

Aspirin for primary prevention of vascular disease in people with diabetes.
by: Haynes, R, et al.
Published: (2009)

MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS
by: Bulbulia, R, et al.
Published: (2007)

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.
by: Armitage, J, et al.
Published: (2010)

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
by: Bulbulia, R, et al.
Published: (2011)

Regarding "Does simvastatin save lives; If so, when and in whom?" - Reply
by: Bulbulia, R, et al.
Published: (2008)

Cost-effective recruitment methods for a large randomised trial in people with diabetes: A Study of Cardiovascular Events iN Diabetes (ASCEND).
by: Aung, T, et al.
Published: (2016)

Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.
by: Armitage, J, et al.
Published: (2010)

Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors.
by: Bowman, L, et al.
Published: (2007)

Aspirin Therapy, Cognitive Impairment, and Dementia—A Review
by: Elizabeth H. Thong, et al.
Published: (2023-02-01)

Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people.
by: Armitage, J, et al.
Published: (2009)

A biomarker-based biological age in UK Biobank: composition and prediction of mortality and hospital admissions
by: Chan, MS, et al.
Published: (2021)

Clinical trials of lipid-modifying agents: design considerations
by: Bowman, L, et al.
Published: (2011)

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
by: Mafham, M, et al.
Published: (2021)

Effects of n-3 fatty acid supplements in diabetes mellitus
by: Ascend Study Collaborative Group, et al.
Published: (2018)

Effects of extended-release niacin with laropiprant in high-risk patients.
by: Landray, M, et al.
Published: (2014)

Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study. Oxford Cholesterol Study Group.
by: Keech, A, et al.
Published: (1996)

Performance of the UKPDS Outcomes Model 2 in a contemporary UK type 2 diabetes trial cohort
by: Keng, MJ, et al.
Published: (2021)

Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration
by: Wardle, J, et al.
Published: (1996)

Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group.
by: Wardle, J, et al.
Published: (1996)

Effects of extended release niacin/laropiprant in 25,673 high-risk individuals receiving statin-based therapy: the HPS2-THRIVE randomized placebo-controlled trial
by: Landray, M, et al.
Published: (2014)

Environmental and genetic risk factors for myopathy in Chinese participants from HPS2-THRIVE
by: Hopewell, J, et al.
Published: (2012)